Shire PLC (SHPG): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Shire ( SHPG) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.2%. By the end of trading, Shire fell $1.67 (-1.8%) to $92 on average volume. Throughout the day, 363,063 shares of Shire exchanged hands as compared to its average daily volume of 324,500 shares. The stock ranged in price between $91.85-$92.85 after having opened the day at $92.69 as compared to the previous trading day's close of $93.67. Other companies within the Drugs industry that declined today were: Oramed Pharmaceuticals ( ORMP), down 7.6%, MediciNova ( MNOV), down 6.7%, Affymax ( AFFY), down 6.5%, and Opexa Therapeutics ( OPXA), down 5.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals, Human Genetic Therapies, and Regenerative Medicine. Shire has a market cap of $17.76 billion and is part of the health care sector. The company has a P/E ratio of 24.1, above the S&P 500 P/E ratio of 17.7. Shares are up 2.7% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Shire a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the positive front, Oxygen Biotherapeutics ( OXBT), up 19.1%, ARCA biopharma ( ABIO), up 18.7%, Celldex Therapeutics ( CLDX), up 17.4%, and Peregrine Pharmaceuticals ( PPHM), up 12.9%, were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead